Burning Rock Biotech Reports Q3 Non-GAAP EPS Loss of RMB 0.17

Key Facts

1Burning Rock Biotech reported a Q3 non-GAAP EPS loss of RMB 0.17.

2The company's revenue reached RMB 134.77 million during the third quarter of 2026.

Amid ongoing headwinds in the emerging biotechnology sector, Burning Rock Biotech has released its financial results for the third quarter of 2026. According to reports, the company posted a non-GAAP loss per share of RMB 0.17. The financial disclosure further revealed that total revenue reached RMB 134.77 million during this quarterly period.

These results arrive as markets closely monitor the performance of specialized healthcare firms, with the reported figures reflecting sustained operational pressures. Regarding the company's financial position, total assets stood at RMB 750.61 million against total liabilities of RMB 253.53 million. This data, sourced from analyst reports, confirms that the net loss widened to RMB 18.41 million due to various operational factors.

The BNR stock price was at $11.99 at the close of September 9, 2026, having traded between a day low of $10.85 and a high of $13.26. With no immediate catalysts listed in the upcoming economic calendar specifically for the biotech sector, investors will be watching the support and resistance levels established during the most recent trading session.